ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

 

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
Avatar

Long-term Results of a Phase 2 Trial of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Chronic Phase of Chronic Myeloid Leukemia

By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Lucia Masarova
By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Lucia Masarova
0 views
January 2, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
Scientific Session 6: Therapeutic Interventions
12:02
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Long-term Impact of Early and Deeper Molecular Response in Newly Dia…

Feat. Y. Do
20:26
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Are TKI Really Safe?

Feat. C. Gambacorti-Passerini
11:40
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Long-term Results of a Phase 2 Trial of Nilotinib 400 Mg Twice Daily…

Feat. L. Masarova